Alkermes plc (ALKS)
| Market Cap | 5.67B |
| Revenue (ttm) | 1.48B |
| Net Income (ttm) | 241.66M |
| Shares Out | 166.25M |
| EPS (ttm) | 1.43 |
| PE Ratio | 23.80 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,701,394 |
| Open | 34.06 |
| Previous Close | 33.73 |
| Day's Range | 33.89 - 34.43 |
| 52-Week Range | 25.17 - 36.48 |
| Beta | 0.39 |
| Analysts | Buy |
| Price Target | 43.43 (+27.32%) |
| Earnings Date | May 5, 2026 |
About ALKS
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramu... [Read more]
Financial Performance
In 2025, Alkermes's revenue was $1.48 billion, a decrease of -5.25% compared to the previous year's $1.56 billion. Earnings were $241.66 million, a decrease of -34.16%.
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for ALKS stock is "Buy." The 12-month stock price target is $43.43, which is an increase of 27.32% from the latest price.
News
Alkermes to Report First Quarter Financial Results on May 5, 2026
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Tuesday, May 5, 2026 to discuss the company's first quarter...
Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced plans to present new data from the Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy type 1 (NT1) at the ...
Findings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the publication of a 56-week post hoc analysis of the effects of LYBALVI® (olanzapine and samidorphan) on negative symptoms in adul...
Top 2 Health Care Stocks That May Implode In April
As of April 1, 2026, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the initiation of the Brilliance Studies, a phase 3 program evaluating the safety and efficacy of alixorexton compared to placebo i...
Alkermes Transcript: Stifel 2026 Virtual CNS Forum
Orexin agonists are poised for a pivotal year, with competitive differentiation driven by dosing flexibility and broad applicability across sleep disorders. Clinical data support durable efficacy, and pipeline expansion targets ADHD and fatigue, while pricing strategies reflect orphan drug trends.
Alkermes Announces Inaugural Alkermes Pathways APN Research Awards™ Program
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced that it will begin accepting applications for its inaugural Alkermes Pathways APN Research Awards™ program on Monday, March 16, 202...
Alkermes to Present at the Stifel 2026 Virtual CNS Forum
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Stifel 2026 Virtual CNS Forum on Tuesday, March 17, 2026 at 8:30 a.m. ET...
Alkermes Transcript: TD Cowen 46th Annual Health Care Conference
The company has solidified its position in sleep medicine through strategic acquisitions and a robust commercial base, enabling aggressive pipeline expansion. Phase III trials for orexin agonists are underway, targeting narcolepsy and related disorders, with additional compounds advancing into ADHD and fatigue.
Alkermes Earnings Call Transcript: Q4 2025
2025 delivered strong revenue and EBITDA growth, driven by proprietary products and the Avadel acquisition. 2026 guidance reflects continued momentum, with LUMRYZ integration, robust pipeline advancement, and disciplined capital allocation positioning the company for long-term growth.
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2025 and Provides Financial Expectations for 2026
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter and year ended Dec. 31, 2025 and provided financial expectations for 2026. To view the detailed fo...
Alkermes plc Announces CEO Succession Plan
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) (Alkermes) today announced that Richard Pops will retire from his role as Chief Executive Officer (CEO), effective July 31, 2026. Alkermes' Board o...
Alkermes to Present at the TD Cowen 46th Annual Health Care Conference
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at ...
Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) (“Alkermes”) and Avadel Pharmaceuticals plc (Nasdaq: AVDL) (“Avadel”) today announced Alkermes' completion of its acquisition of Avadel, a commerci...
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 25, 2026
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Wednesday, Feb. 25, 2026 to discuss the company's fourth qu...
Alkermes Transcript: 44th Annual J.P. Morgan Healthcare Conference
A profitable neuroscience company is accelerating growth with a late-stage Orexin agonist, ALKS 2680, entering Phase 3 for narcolepsy and IH, supported by strong Phase 2 data and a strategic acquisition in sleep medicine. The pipeline targets large, underserved markets and aims for competitive differentiation through flexible dosing and robust data.
Alixorexton Granted Breakthrough Therapy Designation by U.S. FDA for the Treatment of Narcolepsy Type 1
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to alixorexton for the treatment of n...
Alkermes to Present at the 44th Annual J.P. Morgan Healthcare Conference
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 44th Annual J.P. Morgan Healthc...
Avadel Pharmaceuticals Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avadel Pharmaceuticals plc - AVDL
NEW YORK and NEW ORLEANS , Dec. 12, 2025 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
Alkermes Transcript: Piper Sandler 37th Annual Healthcare Conference
Alixorexton shows strong efficacy and safety in NT1 and NT2, with flexible dosing strategies emerging as key for addressing disease heterogeneity. Phase III studies are set, and competitive differentiation will focus on dose flexibility. Oxybates remain relevant for some, but orexins are poised to expand their role, especially in IH.
Alkermes Transcript: Evercore ISI 8th Annual HealthCONx Conference
A transformational year included positive NT1/NT2 data, strategic Avadel acquisition, and strong commercial performance. Robust phase II results support phase III trials for ALKS 2680, with a focus on expanding orexin programs and maintaining profitability.
Alkermes to Participate in Two Upcoming Investor Conferences
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) announced today that management will participate in two upcoming investor conferences. 8th Annual Evercore Healthcare Conference Date/Time: Wednesd...
Alkermes Transcript: Jefferies London Healthcare Conference 2025
Recent NT2 data revealed strong efficacy and safety for orexin agonists, supporting flexible dosing and broad clinical benefit. Strategic moves, including the Avidel acquisition, position for market expansion, while confidence grows for future indications and ongoing pipeline development.
Alkermes raises offer for Avadel after Lundbeck bid
Alkermes said on Wednesday it has sweetened its offer to buy Avadel Pharmaceuticals , beating a rival bid from Denmark's Lundbeck and valuing the sleep disorder drugmaker at up to $2.37 billion.
Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTIO...